Dr. Mark Egerton
Mark has more than 20 years’ patent experience specialising in cell and molecular biology, protein chemistry, immunology, biochemistry, genomics and medical devices.
Mark is committed to working with clients such as universities and startup companies to protect early stage inventions in Australia and major foreign jurisdictions such as Europe, USA, Japan and China. Mark brings a sound understanding of patent strategy to his role, particularly with regard to the complexities of patenting biotechnological inventions, where there are significant differences in law practice across different jurisdictions.
Mark’s previous scientific experience includes working as a Post-Doctoral Research Scientist in the fields of immunology and signal transduction at the National Institutes of Health (USA) and at the Queensland Institute of Medical Research. Mark’s expertise and experience are highly prized by domestic and international businesses, universities and research institutes that are engaged in developing biotechnology inventions.
Mark joined Fisher Adams Kelly Callinans (now Spruson & Ferguson) in 1997 and became a partner in 2001. Mark frequently contributes to public debates particularly around patent protection issues that arise in the biotechnology industry.
Bachelor of Science (Hons) - The Walter and Eliza Hall Institute University of Melbourne
PhD - The Walter and Eliza Hall Institute University of Melbourne
Registered Australian and New Zealand Patent Attorney
The Institute of Patent and Trade Mark Attorneys Australia (IPTA)
Australia's Biotechnology Organisation (AusBiotech)
No Articles by this Author